#United States #San Diego #Neurelis #AAN #Diazepam

Neurelis Showcases Important Insights on Seizure Treatment at AAN Annual Meeting

Neurelis, Inc., a leader in neuroscience solutions, is set to unveil pivotal analyses regarding the treatment of seizures using diazepam nasal spray at the upcoming American Academy of Neurology (AAN) Annual Meeting. Scheduled to take place from Ap... 5-9, 2025, in San Diego, this conference serves as a key platform for advancing knowledge and research in neurology.

The presentations will highlight three significant poster sessions that delve into various aspects of seizure treatment using diazepam nasal spray, specifically focusing on its application during critical episodes of frequent seizures. The featured analyses are derived from clinical studies, offering insights into how this immediate-use seizure medication can effectively manage episodes.

Key Presentations at AAN

As part of its participation in the meeting, Neurelis will present:

1. Treatment of Status Epilepticus (SE) with Diazepam Nasal Spray

This poster presentation will analyze two long-term, open-label safety studies assessing treatment for early episodes of SE in patients aged 2-65. Early episodes are defined as any seizures that continue beyond set time points. With a dataset comprising 671 events from 97 patients, results have indicated that diazepam nasal spray provided timely seizure control without significant adverse outcomes, showcasing its efficacy and safety profile. This is particularly significant given the pressing nature of SE, where timely intervention is essential for patient outcomes.

2. Addressing Prolonged Seizures

In a post hoc analysis incorporating data from a safety study, Neurelis examined the effectiveness of diazepam nasal spray in managing prolonged seizures lasting between 5-15 minutes, focusing on its use within seizure clusters. An intriguing finding was that the commonality of needing second doses remained low, pointing to the consistent effectiveness of the first dose and suggesting the medication's potential to control seizures early in their onset across demographic subgroups.

3. Acute Cluster Treatment Recommendations

Using data obtained from their long-term safety study, Neurelis aims to explore expert consensus recommendations to halt acute seizure clusters effectively. The analysis demonstrated that timely administration of diazepam nasal spray significantly improves rapid seizure termination outcomes, further emphasizing the importance of immediate treatment – especially if administered within minutes of seizure onset.

Reaffirming Commitment to Neuroscience

"We are excited to be part of this year's AAN Annual Meeting, as it offers a valuable opportunity to engage with the neurology community regarding the latest findings on epilepsy treatments," stated Adrian L. Rabinowicz, MD, Chief Medical Officer of Neurelis. The company aims to promote discussions that can lead to improved quality of life for individuals living with epilepsy and various neurological disorders through ongoing clinical research.

Neurelis prides itself on innovating solutions like VALTOCO®, a diazepam nasal spray that the FDA has approved for acute treatment needs in patients aged six and above experiencing seizure clusters. This highlights the ongoing commitment of Neurelis to enhance treatment options where unmet medical needs are most significant.

As the AAN showcases a commitment to advancing brain health and improving treatments for brain diseases, the contributions from Neurelis align seamlessly with this mission. The emphasis on scientific rigor and understanding patient needs through robust research continues to be a cornerstone of their work in neurology.

For more information about Neurelis and its innovative approaches, visit their website at Neurelis.